41results about How to "Good lipid-lowering activity" patented technology

The invention relates to an anti-obesity compound and a preparing method and application thereof. The compound structural formula is shown as the formula (I), or the formula (II) or the formula (III).The anti-obesity compound has high lipid-decreasing activity and is capable of effectively suppressing fat cell differentiation and reducing the lipid level in fat cells, high in stability and low intoxicity. In addition, the anti-obesity compound is prepared through a three-step method, the preparing process is simple and short in time and includes few reaction steps, and aftertreatment is easy.

The invention discloses new dihydrogen homoisoflavonoid, and a preparation method and application thereof. The new dihydrogen homoisoflavonoid is separated to extract polygonatum sibiricum. Experiments prove that the dihydrogen homoisoflavonoid can remarkably inhibit lipid accumulation in Hep-G2 cells, also can remarkably reduce the triglyceride (TG) content and the total cholesterol (TC) content of the cells, is more excellent that a positive control medicine simvastatin in the aspect of reducing the TG, and has excellent blood fat-reducing activity. The discovery of the new dihydrogen homoisoflavonoid provides a new lead compound for developing a new blood fat-reducing medicine, and good development and application prospect is achieved. The preparation process is simple, stable and reliable, the purity of the compound is high (above 98 percent), industrialized popularization is facilitated, a new approach is opened up for research and development of the blood fat reducing medicines, and good social and economic benefits are achieved.

The invention discloses a marine fungus, novel skeleton meroterpenoid derivatives prepared from the marine fungus as well as a preparation method and application of the novel skeleton meroterpenoid derivatives. The marine fungus Aspergillus terreus GZU-31-1 is preserved in Guangdong Microbiological Culture Collection Center on December 17, 2019 and has a preservation number of GDMCC No:60789. Sixnovel skeleton meroterpenoid derivatives are separated from fermented liquid of the marine fungus, have novel structures and are capable of remarkably reducing the activity of triglyceride; particularly, when the concentrations of the compounds 1-5 are 2 microliters and 5 microliters, the content of triglyceride in cells is remarkably reduced; especially the lipid decreasing activity of the compound 1 at a concentration of 5 microliters is even superior to that of a positive control, namely berberine at the same concentration. The compounds provided by the invention have a great application value to lipid decreasing and can be prepared into lipid decreasing drugs for use.

The invention discloses a gynostemma pentaphylla extract and a preparation method thereof; the gynostemma pentaphylla extract contains 50-99% by mass of a saponin compound; the invention specificallydiscloses a structure of the saponin compound. The gynostemma pentaphylla extract provided by the invention has remarkable lipid-lowering activity, and the preparation method is simple and convenientand has good economic benefits and application prospects.

The invention discloses a preparation and purification method of chitosan oligosaccharide. The method comprises the following steps of: taking chitosan dried to constant weight, adding a HCl solution,and adjusting a pH value; adding a chitosanase solution, performing insulation for 2h-6h, and then heating the material in a boiling water bath and performing enzyme deactivation; performing rotary evaporation and condensation at 50 DEG C or lower, and then placing the material in a freeze dryer to obtain a crude chitosan oligosaccharide extract; dissolving the crude chitosan oligosaccharide extract in a NH4HCO3 solution, and after completely dissolved, filtering the material through a filter membrane to obtain a chitosan oligosaccharide solution; dumping resin into a chromatography column, using NH4HCO3 for flushing resin until the resin is compacted, slowly dumping the chitosan oligosaccharide solution into the chromatography column, collecting an eluate, and performing rotary evaporation and condensation to obtain chitosan oligosaccharide. The method has the advantages that the chitosanase is used to decompose chitosan to prepare chitosan oligosaccharide, and the chitosan oligosaccharide with a single polymerization degree is prepared by gel column chromatographic separation and purifying, the purity can achieve more than 97%, the prepared chitosan oligosaccharide has good hypolipidemic activity, protects the liver, and enhances the antioxidant activity of the body.

The invention belongs to the technical field of pharmaceutical chemistry, and relates to hypolipidemic compounds, a preparation method thereof and a purpose thereof. According to the novel compounds with hypolipidemic activity, a rubiaceae plant geophilaherbacea is adopted as a raw material, and novel 2,6-phenethanol dihydroxybenzoate is obtained by separation and identification through a solvent extraction and chromatography method. According to the invention, substituted aryl acid and substituted aryl alcohol are adopted as raw materials, and are subject to a reaction in an appropriate solvent with the effect of a catalyst under a certain temperature, such that 2,6-phenethanol dihydroxybenzoate and similar substances are produced. The compounds show substantial hypolipidemic effects in hypolipidemic models, and can be used for preparing novel hypolipidemic medicines. The extraction, separation, synthesis and preparation methods disclosed by the invention are advantaged in mild reaction condition, easy operation, and high yield.

The invention relates to a resveratrol derivative and application thereof to a medicament, and particularly discloses a compound shown as a formula I or pharmaceutically acceptable salt, ester, solvate and stereoisomers thereof. In the formula I, R1, R2 and R3 are independently selected from a hydrogen atom, C1 to C3 alkyl or a substituted group shown as a formula i; at least one of R1, R2 and R3 is the substituted group shown as the formula i; R is selected from the hydrogen atom, substituted or unsubstituted C1 to C5 alkyl, substituted or unsubstituted C3 to C6 naphthenic base, benzyl or phenyl; R4 and R5 are independently selected from the hydrogen atom, the substituted or unsubstituted C1 to C5 alkyl, or substituted or the unsubstituted C3 to C6 naphthenic base; and n is an integer of between 1 and 5. The invention also discloses a medicinal composition containing the compound shown as the formula I, and the application of the compound shown as the formula I to the preparation of a medicament for treating and / or preventing cardiovascular and cerebrovascular diseases. The compound shown as the formula I can be effectively used for treating and / or preventing the cardiovascular and cerebrovascular diseases such as hyperlipemia.

The invention discloses composite seaweed polysaccharide oral liquid for reducing blood lipid and a preparation method of the composite seaweed polysaccharide oral liquid. The composite seaweed polysaccharide oral liquid for reducing blood lipid is prepared from the following components in percentage by mass: 60-90% of a seaweed polysaccharide extract, 1-10% of a haw extract, 1-10% of a lotus leaf extract, 1-10% of a ginkgo leaf extract, 1-10% of a mulberry leaf extract and 0.01-10% of a sweetening agent, wherein the seaweed polysaccharide extract is obtained through extraction with high-pressure steam. The preparation method comprises the following steps of mixing the components in percentage by mass to obtain a mixture, performing cold storage on the mixture, performing centrifugation to obtain a supernatant, performing filling, performing covering, and performing sterilization so as to obtain the composite seaweed polysaccharide oral liquid for reducing blood lipid. According to the composite seaweed polysaccharide oral liquid and the preparation method thereof disclosed by the invention, polysaccharide and polyphenol substances having the efficacy of reducing blood lipid are in synergy and are compounded, the preparation method is simple in steps, the synergistic interaction of seaweed polysaccharides and polyphenols is used for strengthening the efficacy of the seaweed polysaccharides for reducing blood lipid, and the purpose of enhancing the efficacy of the finished products for reducing blood lipid can be achieved.

An Se-enriched garlic product for haelth-care and medical purposes is prepared through preparing aqueous solution of acetic acid or ethanol, adding peeled Se-riched garlic cloves, breaking, adding a small portion of solution, mashing, quickly adding the rest of the said aqueous solution, loading in bottle with cap, oscillation extracting for 0.5-3 hr, laying aside, and oscillating several times per day to guarantee uniform mixing. Its advantages are high hypolipemic activity and selective suppression to cancer cells.

The invention relates to a resveratrol derivative and a medical application thereof, and in particular discloses a compound in a formula I as shown in the specification or pharmaceutically acceptable salt, ester, solvate and stereoisomer thereof, wherein R1, R2 and R3 are respectively independently selected from hydrogen atom, C1-C3 alkyl groups, or a substituent group in a formula i as shown in the specification, at least one of R1, R2 and R3 is selected from the C1-C3 alkyl groups, and simultaneously at least one of R1, R2 and R3 is selected from the substituent group in the formula i; R is selected from hydrogen atom, substituted or unsubstituted C1-C5 alkyl groups, substituted or unsubstituted C3-C6 naphthenic groups, benzyl groups or phenyl groups; and R4 and R5 are respectively independently selected from hydrogen atom, substituted or unsubstituted C1-C5 alkyl groups, or substituted or unsubstituted C3-C6 naphthenic groups. The invention also discloses a pharmaceutical composition containing the compound in the formula I, and the application of the compound in the formula I in preparing medicines for treating and / or preventing cardiovascular and cerebrovascular diseases. The compound in the formula I provided by the invention can be effectively used for treating and / or preventing the cardiovascular and cerebrovascular diseases such as hyperlipidaemia.

The invention provides a benzophenone dimer compound, or a pharmaceutically acceptable salt or an optical isomer of the benzophenone dimer compound. Meanwhile, the invention further provides application of the compound in preparation of products for lowering lipid, whitening and the like.

The invention discloses a dihydroartemisinin-containing carboxy phenol / ester phenol / amido phenol conjugate. The conjugate or a racemate, stereoisomer and tautomer thereof and a pharmaceutically acceptable salt of the conjugate have a structural general formula as shown in a formula I, wherein n is equal to 2 or 3, X is an alkoxyl, a hydroxyl, an amino group or -O(CH2)b-DHA, Y is -H or an alkoxyl,Z is an alkenyl and an alkyl or has no groups, b is equal to 2 or 3, and DHA represents for dihydroartemisinin. The invention further discloses a synthesis method of the dihydroartemisinin-containingcarboxy phenol / ester phenol / amido phenol conjugate and an application of the conjugate as a drug for resisting to tuberculosis and diabetes mellitus, reducing blood fat and inhibiting interleukin-17.

The invention relates to a synthetic method of pyridine alkaloid compounds and applications of these compounds. The compounds have the structural general formula as the specification, wherein R is selected from one of ethanol, allyl group, bromoethane, dimethyl aminoethane, benzyl group and N-(2-ethyl)pyrrolidine. The synthetic method of the skeleton structure includes: 1) synthesis of an intermediate compound: performing a reaction at 0 DEG C, wherein a compound A (Penipyridone A) and glacial acetic acid are reactants, EDCI is a condensating agent, DMAP is a catalyst and anhydrous dichloromethane is a solvent; 2) synthesis of a target compound: performing a reaction on the intermediate compound with halogenated hydrocarbon with K2CO3 being an alkali and anhydrous acetone being a solvent,wherein pyridone is subjected to isomerization, thus preparing the target compound. The synthetic method employs accessible raw materials, is simple in operation and is simplified in synthetic route,and is an effective synthesis route for synthesizing the pyridine compounds. Besides, the compounds D1 and D6 have excellent development and application prospect as lipid lowering drugs.

The invention provides a medicated diet therapy product composition for hyperlipemia and fatty liver. The medicated diet therapy product composition is prepared from the following raw materials in parts by weight: 1-15 parts of hippophae rhamnoides leaves, 1-20 parts of moringa oleifera leaves, 1-15 parts of chicory, 1-20 parts of emblic leafflower fruits, 1-20 parts of purslane, 1-20 parts of cassia seeds, 1-15 parts of wild radix puerariae, 1-15 parts of fructus perillae, 1-20 parts of fructus cannabis, 1-16 parts of kelp, 1-15 parts of lotus leaves, 0.1-3 parts of chitosan oligosaccharide and 0.5-5 parts of xylooligosaccharide. The invention also provides a preparation method of the medicated diet and dietary therapy product composition for hyperlipidemia and fatty liver. The medicateddiet and dietary therapy product composition for hyperlipidemia and fatty liver has the characteristics of definite curative effect, clear action target and pharmacological effect, wide raw material source, low cost, simple preparation method, high patient compliance and the like, and can effectively prevent and treat hyperlipidemia and relieve related symptoms caused by hyperlipidemia.

The invention discloses application of a sesquiterpene glycoside monomeric compound in preparation of lipid-lowering drugs or health care products. The chemical formula of the sesquiterpene glycoside monomeric compound is nerolidol-3-O-alpha-L-rhaminopyranosyl- (1 to 2)-[alpha-L-rhaminopyranosyl-(1 to 6)]-beta-D-glucopyranoside.

The invention discloses a saffron crocus petal refined alcohol extract, and a preparation method and application thereof, and belongs to the technical field of saffron crocus active ingredient extraction. The preparation method comprises the following steps: S1, carrying out low-temperature plasma treatment; S2, carrying out subzero treatment; S3, carrying out superfine grinding treatment; S4, performing low-temperature vacuum drying treatment; S5, carrying out primary alcohol extraction; S6, carrying out secondary alcohol extraction; and S7, carrying out purification treatment. According to the saffron crocus petal refined alcohol extract, and the preparation method and application thereof provided by the invention, after the prepared saffron crocus petal refined alcohol extract is subjected to intragastric administration on a mouse, the weight increment and the food intake of the mouse are not remarkably different from those of a normal control group; therefore, the saffron crocus petal refined alcohol extract prepared by the method provided by the invention has relatively low influence on the appetite of the mouse and relatively small stimulation on the digestive system of the mouse. The saffron crocus petal refined alcohol extract prepared by the method disclosed by the invention has obvious blood fat reducing activity, that is, the saffron crocus petal refined alcohol extract prepared by the method disclosed by the invention is high in extraction rate and relatively high in activity.

The invention provides a eucheuma blood fat reducing tetrapeptide and an application thereof, and belongs to the technical field of blood pressure reducing oligopeptide. The amino acid sequence of theeucheuma blood fat reducing tetrapeptide is Phe-Tyr-Lys-Ala (FYKA), and the eucheuma blood fat reducing tetrapeptide has good fat reducing activity. The eucheuma blood fat reducing tetrapeptide can be applied to preparation of blood fat reducing drugs, health care products and food additives. The eucheuma blood fat reducing tetrapeptide can remarkably reduce fat accumulation amount of oleic acidinduced hepatic cells, remarkably reduces the level of triglyceride (TG) and total cholesterol (TC) in the hepatic cells, has good blood fat reducing activity and can be used for developing the bloodfat reducing related drugs, the health care products and special medical food.

The invention provides a eucheuma blood fat reducing tetrapeptide and an application thereof, and belongs to the technical field of blood pressure reducing oligopeptide. The amino acid sequence of theeucheuma blood fat reducing tetrapeptide is Phe-Tyr-Lys-Ala (FYKA), and the eucheuma blood fat reducing tetrapeptide has good fat reducing activity. The eucheuma blood fat reducing tetrapeptide can be applied to preparation of blood fat reducing drugs, health care products and food additives. The eucheuma blood fat reducing tetrapeptide can remarkably reduce fat accumulation amount of oleic acidinduced hepatic cells, remarkably reduces the level of triglyceride (TG) and total cholesterol (TC) in the hepatic cells, has good blood fat reducing activity and can be used for developing the bloodfat reducing related drugs, the health care products and special medical food.

The invention discloses a hydrogen sulfide donor type compound containing a 1,2-dithiole-3-thioketone structure and blood fat reducing application thereof, and belongs to the technical field of biological medicines. The compound is similar with Fibrates drugs in structure, can reduce level of triglyceride and cholesterol, and has the effect of being broad in spectrum and reducing blood fat. Besides, the compound can slowly release hydrogen sulfide to bring multiple cardiovascular protection effects such as oxidative stress resistance, oxidation resistance improvement and the anti-inflammationeffect into play.

The invention provides blood lipid reducing oligo-peptides of miichthys miiuy flesh. A preparation method specifically comprises the following steps: performing flesh defatting and enzymatic hydrolysis with a compound enzyme on the miichthys miiuy flesh taken as a raw material to obtain enzymatic hydrolysate, and performing ultrafiltration, desalting with macroporous resin, chromatography with anion exchange resin, gel column chromatography and reversed-phase high-performance liquid chromatography separation and purification on the enzymatic hydrolysate to obtain the blood lipid reducing oligo-peptides Val-Ile-Ala-Pro-Trp (VIAPW), the molecular weight being measured to be 584.72Da by ESI-MS (electrospray ionization mass spectrometry). By the VIAPW, adipogenesis genes can be reduced, oxidation of fatty acid beta can also be promoted, generation of lipid is reduced, LXRalpha and LXRbeta are activated, the blood lipid reducing level is higher than the lipid generation capability, and higher blood lipid reducing activity is achieved. The VIAPW has the advantages of safe, no toxic or side effects, high blood lipid reducing activity and the like, and can be developed as a blood lipid reducing medicament and health food.

The invention relates to a resveratrol derivative and application thereof to a medicament, and particularly discloses a compound shown as a formula I or pharmaceutically acceptable salt, ester, solvate and stereoisomers thereof. In the formula I, R1, R2 and R3 are independently selected from a hydrogen atom, C1 to C3 alkyl or a substituted group shown as a formula i; at least one of R1, R2 and R3 is the substituted group shown as the formula i; R is selected from the hydrogen atom, substituted or unsubstituted C1 to C5 alkyl, substituted or unsubstituted C3 to C6 naphthenic base, benzyl or phenyl; R4 and R5 are independently selected from the hydrogen atom, the substituted or unsubstituted C1 to C5 alkyl, or substituted or the unsubstituted C3 to C6 naphthenic base; and n is an integer of between 1 and 5. The invention also discloses a medicinal composition containing the compound shown as the formula I, and the application of the compound shown as the formula I to the preparation of a medicament for treating and / or preventing cardiovascular and cerebrovascular diseases. The compound shown as the formula I can be effectively used for treating and / or preventing the cardiovascular and cerebrovascular diseases such as hyperlipemia.

The invention discloses new dihydrogen homoisoflavonoid, and a preparation method and application thereof. The new dihydrogen homoisoflavonoid is separated to extract polygonatum sibiricum. Experiments prove that the dihydrogen homoisoflavonoid can remarkably inhibit lipid accumulation in Hep-G2 cells, also can remarkably reduce the triglyceride (TG) content and the total cholesterol (TC) content of the cells, is more excellent that a positive control medicine simvastatin in the aspect of reducing the TG, and has excellent blood fat-reducing activity. The discovery of the new dihydrogen homoisoflavonoid provides a new lead compound for developing a new blood fat-reducing medicine, and good development and application prospect is achieved. The preparation process is simple, stable and reliable, the purity of the compound is high (above 98 percent), industrialized popularization is facilitated, a new approach is opened up for research and development of the blood fat reducing medicines, and good social and economic benefits are achieved.

The invention relates to a drug used for reducing blood fat, and a preparation method thereof. The drug is used for treating hyperlipidemia and / or atherosclerosis. The drug is capable of increasing the uptake ratio of hepatocytes on low density lipoprotein, and reducing serum total cholesterol, serum triglyceride, and serum low density lipoprotein cholesterol of mouse obviously; the effect of the drug is similar to that of simvastatin; it is shown that the drug possesses excellent blood fat reducing activity, and can be used in treatment of hyperlipidemia and atherosclerosis.

The invention discloses a marine fungus, a novel skeleton heteroterpene derivative prepared therefrom, a preparation method and application thereof. The marine fungus Aspergillus terreus GZU‑31‑1 was preserved in the Guangdong Provincial Microbial Culture Collection Center on December 17, 2019, and the preservation number is GDMCC No: 60789. From its fermentation broth, 6 novel skeleton hybrids were obtained. Terpene derivatives, which are novel in structure, also have significant triglyceride-lowering activity, especially compound 1‑5, when the concentration is 2 μM and 5 μM, the content of triglyceride in cells is significantly reduced, especially compound 1. Its lipid-lowering activity at a concentration of 5 μM is even better than the positive control berberine at the same concentration; the compound of the present invention has great application value in lipid-lowering, and can be prepared as a lipid-lowering drug for application.

The invention provides a nibea albiflora swimming bladder-originated antihyperlipidemic hexapeptide and application thereof and belongs to the technical field of antihyperlipidemic oligopeptides. Thenibea albiflora swimming bladder-originated antihyperlipidemic hexapeptide is a peptide composed of amino acid sequences shown as SEQ ID NO: 1, and the ESI-MS (electrospray ionization mass spectrometry) measured molecular weight of the nibea albiflora swimming bladder-originated antihyperlipidemic hexapeptide is 687.75 Da. The invention relates to application of the nibea albiflora swimming bladder-originated antihyperlipidemic hexapeptide to preparing antihyperlipidemic drugs and / or healthcare products and / or food additives. The nibea albiflora swimming bladder-originated antihyperlipidemic hexapeptide can reduce the expression level of lipogenic genes, promote beta-oxidation of fatty acids, reduce lipid generation and achieve high lipid-lowering activity. The nibea albiflora swimming bladder-originated antihyperlipidemic hexapeptide can be applied to developing antihyperlipidemic drugs, healthcare products and food additives.

The invention discloses Tigliane-type diterpenoid compounds and a pharmaceutically acceptable derivative thereof. The general formula of the Tigliane-type diterpenoid compounds is as shown in the specification. The inventor applies the Tigliane-type diterpenoid compounds in the aspects of lowering lipid and treating obesity for the first time. Lipid-lowering activity experimental results show thatthe Tigliane-type diterpenoid compounds have low cytotoxicity and good lipid-lowering activity and are expected to be developed into new lipid-lowering drugs or health products. Especially the compound YGGZ-2 has the potential of being developed into new lipid-lowering or fat-reducing drugs or health products.

The invention provides a blood lipid-lowering hexapeptide derived from the swim bladder of yellow croaker and its application, which belongs to the technical field of blood lipid-lowering oligopeptides. The peptide consists of the amino acid sequence of SEQ ID NO: 1, and its molecular weight determined by ESI-MS is 687.75Da. Application of the above blood lipid-lowering hexapeptide in the preparation of blood lipid-lowering medicines and / or health care products and / or food additives. The blood lipid-lowering hexapeptide of the present invention can down-regulate the expression level of lipid-forming genes, promote the beta oxidation of fatty acids, and reduce the generation of lipids. It is used in the development of blood lipid-lowering drugs, health care products and food additives.

The invention discloses composite seaweed polysaccharide oral liquid for reducing blood lipid and a preparation method of the composite seaweed polysaccharide oral liquid. The composite seaweed polysaccharide oral liquid for reducing blood lipid is prepared from the following components in percentage by mass: 60-90% of a seaweed polysaccharide extract, 1-10% of a haw extract, 1-10% of a lotus leaf extract, 1-10% of a ginkgo leaf extract, 1-10% of a mulberry leaf extract and 0.01-10% of a sweetening agent, wherein the seaweed polysaccharide extract is obtained through extraction with high-pressure steam. The preparation method comprises the following steps of mixing the components in percentage by mass to obtain a mixture, performing cold storage on the mixture, performing centrifugation to obtain a supernatant, performing filling, performing covering, and performing sterilization so as to obtain the composite seaweed polysaccharide oral liquid for reducing blood lipid. According to the composite seaweed polysaccharide oral liquid and the preparation method thereof disclosed by the invention, polysaccharide and polyphenol substances having the efficacy of reducing blood lipid are in synergy and are compounded, the preparation method is simple in steps, the synergistic interaction of seaweed polysaccharides and polyphenols is used for strengthening the efficacy of the seaweed polysaccharides for reducing blood lipid, and the purpose of enhancing the efficacy of the finished products for reducing blood lipid can be achieved.

The invention relates to cyclocarya paliurus mogroside. The cyclocarya paliurus mogroside is obtained by performing water or alcohol extraction on cyclocarya paliurus leaves, passing through macroporous adsorption resin, and sequentially eluting with water and an ethanol solution. The preparation method comprises the following steps: adding a proper amount of cyclocarya paliurus leaves into water or ethanol, heating, refluxing and extracting, combining extracting solutions, and concentrating under reduced pressure to obtain a concentrated solution; enabling the concentrated solution to pass through a macroporous adsorption resin column, and sequentially eluting with water, a 15-25% ethanol solution and a 75-85% ethanol solution respectively; concentrating the 75-85% ethanol elution part under reduced pressure until no alcohol smell exists, adding water for suspension, extracting with ethyl acetate, and recovering the solvent to obtain a cyclocarya paliurus leaf sweet part; decoloring sweet parts of the cyclocarya paliurus leaves; and drying to obtain the cyclocarya paliurus mogroside. The cyclocarya paliurus mogroside or the cyclocarya paliurus mogroside prepared by the method can be used for preparing a medicine with a lipid-lowering function, or can be used for common food or health food, or can be directly used as a food additive such as a sweetening agent, an aromatic and the like.